HASBROUCK HEIGHTS, N.J., July 11, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the completion of enrollment for Study NX02-0020, one of the Company’s Phase 3 studies of NX-1207 for benign prostatic hyperplasia (BPH). The NX02-0020 study started in July 2011 and involved men who had previously participated in one of the earlier NX-1207 studies for BPH and in the current trial wished an open label injection of NX-1207. A recent Safety Committee meeting update on the trial indicated no significant safety concerns to date. Recruitment of new participants for this ongoing study is now completed. Efficacy results for Study NX02-0020 are expected near the end of this year.
